JPMorgan Chase & Co. Issues Positive Forecast for Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price

Adaptive Biotechnologies (NASDAQ:ADPT) had its price objective raised by equities researchers at JPMorgan Chase & Co. from $20.00 to $21.00 in a research note issued on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 33.45% from the stock’s previous close.

ADPT has been the topic of a number of other research reports. TD Cowen reissued a “buy” rating on shares of Adaptive Biotechnologies in a research report on Friday. BTIG Research increased their target price on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. Morgan Stanley assumed coverage on shares of Adaptive Biotechnologies in a research note on Monday, December 1st. They set an “equal weight” rating and a $21.00 price objective on the stock. Finally, Piper Sandler set a $21.00 price objective on shares of Adaptive Biotechnologies in a research note on Friday. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $17.56.

Adaptive Biotechnologies Stock Down 4.5%

ADPT traded down $0.73 on Friday, reaching $15.74. 3,403,512 shares of the company traded hands, compared to its average volume of 2,048,769. The company has a market cap of $2.40 billion, a P/E ratio of -29.14 and a beta of 2.18. Adaptive Biotechnologies has a one year low of $6.26 and a one year high of $20.76. The firm has a fifty day simple moving average of $17.10 and a two-hundred day simple moving average of $15.16.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 31.50% and a negative return on equity of 58.40%. The business had revenue of $71.68 million for the quarter, compared to analyst estimates of $59.38 million. During the same period last year, the company posted ($0.23) earnings per share. The company’s quarterly revenue was up 51.0% compared to the same quarter last year. On average, equities analysts forecast that Adaptive Biotechnologies will post -0.92 earnings per share for the current year.

Insider Activity at Adaptive Biotechnologies

In related news, insider Sharon Benzeno sold 308,477 shares of Adaptive Biotechnologies stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $16.91, for a total value of $5,216,346.07. Following the completion of the sale, the insider directly owned 296,791 shares in the company, valued at $5,018,735.81. This trade represents a 50.97% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Kyle Piskel sold 162,820 shares of the business’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $19.50, for a total transaction of $3,174,990.00. Following the sale, the chief financial officer directly owned 216,637 shares in the company, valued at approximately $4,224,421.50. This represents a 42.91% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 1,610,316 shares of company stock worth $27,714,816. 6.40% of the stock is owned by insiders.

Institutional Trading of Adaptive Biotechnologies

Several institutional investors and hedge funds have recently bought and sold shares of ADPT. Brighton Jones LLC increased its stake in shares of Adaptive Biotechnologies by 3.1% in the third quarter. Brighton Jones LLC now owns 23,301 shares of the company’s stock worth $349,000 after acquiring an additional 700 shares during the period. Bouvel Investment Partners LLC grew its position in Adaptive Biotechnologies by 2.2% during the 3rd quarter. Bouvel Investment Partners LLC now owns 42,878 shares of the company’s stock worth $641,000 after purchasing an additional 904 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in shares of Adaptive Biotechnologies by 3.1% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 30,512 shares of the company’s stock valued at $355,000 after buying an additional 910 shares during the last quarter. California State Teachers Retirement System lifted its holdings in Adaptive Biotechnologies by 1.0% in the second quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock valued at $1,145,000 after acquiring an additional 933 shares during the period. Finally, Captrust Financial Advisors boosted its position in Adaptive Biotechnologies by 7.6% in the 2nd quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock worth $184,000 after purchasing an additional 1,119 shares in the last quarter. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Adaptive Biotechnologies News Roundup

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Q4 results beat consensus: ADPT reported a loss of $0.09/share vs. a $0.19 expected loss and revenue of $71.7M (≈+51% YoY), materially above Street revenue expectations — a clear operational beat. GlobeNewswire: Press Release
• Positive Sentiment: Market reaction initially positive: several outlets and traders reacted to the beat with upside moves and headlines noting a rally after the results. Investing.com: Soars After Beating Q4
• Neutral Sentiment: Earnings details and management commentary are available — read the full call transcript for guidance commentary, product/partner updates and sales trends that could drive future quarters. Seeking Alpha: Q4 2025 Call Transcript
• Neutral Sentiment: Analysts and metric breakdowns: coverage and write-ups compare key model metrics vs. estimates — useful if you want the line-item context behind the beat. Zacks: Key Metrics vs. Estimates
• Negative Sentiment: Significant insider selling ahead of/around results: CEO Chad Robins sold ~125k shares (~$2.3M) and other insiders also sold tens of thousands of shares in early February — a potential headwind for sentiment. SEC filing / MarketBeat reporting on insider sales
• Negative Sentiment: Shares are trading lower on the session with above-average volume, suggesting profit-taking and reaction to insider sales may be outweighing the headline beat in the short term. MarketBeat: Earnings & Trading Note

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.